Cannabis and diabetes

Cannabis and diabetes are two topics that often intersect when discussing appetite, sugar levels, metabolism, or the potential effects of cannabinoids on the body. It is also common for questions to arise regarding whether cannabis use can affect glucose control, alter the perception of a blood sugar drop, or interfere with a diabetic person’s habits.

That is why it is advisable to approach this relationship with caution. It is not about presenting cannabis as a solution for diabetes, but rather about understanding what questions exist, what precautions should be taken into account, and why no person with diabetes should modify their treatment without medical supervision.

What is diabetes and why does it require medical control

Diabetes mellitus is a metabolic disease characterized by elevated blood glucose levels. It occurs when the pancreas does not produce enough insulin, when the body does not use it correctly, or both. Insulin is the hormone that allows glucose to enter cells and be used as energy, so when this mechanism fails, sugar accumulates in the blood with consequences that, in the long term, affect the kidneys, eyes, nerves, and cardiovascular system.

There is no single type of diabetes. Although in the collective imagination people speak of “diabetes” as if it were a single disease, there are actually at least four well-differentiated forms:

Type 1 diabetes. This is an autoimmune disease in which the immune system itself destroys the cells of the pancreas responsible for producing insulin. It generally appears in childhood or youth, although it can be diagnosed at any age. People with type 1 are dependent on insulin for life.

Type 2 diabetes. This is the most frequent, representing about 90% of cases. Here the problem is not the total absence of insulin, but that the body develops resistance to it and the pancreas ends up being unable to compensate for that demand. It is closely related to lifestyle, although it also has a significant genetic component. Its treatment can range from changes in diet and exercise to oral medication or insulin.

Gestational diabetes. It appears during pregnancy in women who did not have diabetes previously. It occurs because pregnancy hormones can reduce insulin sensitivity. It generally disappears after childbirth, but it increases the risk of developing type 2 diabetes in the future.

Other specific types. This group includes less common but equally relevant forms. Among them are LADA (Latent Autoimmune Diabetes in Adults), which is a slow-onset autoimmune form in adults that is sometimes confused with type 2. MODY (Maturity-Onset Diabetes of the Young), of genetic origin and with its own characteristics. And type 3c diabetes, which appears as a consequence of pancreatic diseases such as chronic pancreatitis or pancreatic cancer.

The endocannabinoid system and its relationship with metabolism

To understand why cannabinoids might have some influence on diabetes, one must first talk about the endocannabinoid system. This system is one of the most widespread in the human body. Furthermore, it regulates functions as diverse as appetite, energy metabolism, inflammation, insulin sensitivity, and pancreatic function.

The endocannabinoid system is made up of three main elements: cannabinoid receptors (mainly CB1 and CB2), endocannabinoids that the body itself produces naturally (such as anandamide and 2-AG), and the enzymes that synthesize and degrade them.

What is relevant here is that these receptors are present in tissues directly involved in diabetes:

• In the pancreas, where CB1 and CB2 receptors participate in the regulation of insulin and glucagon secretion.
• In adipose tissue and the liver, where the endocannabinoid system influences the metabolism of fats and glucose.
• In skeletal muscle, where it affects glucose uptake and insulin sensitivity.
• In the brain, where it regulates appetite and eating behavior, two key factors in type 2 diabetes.

It has been observed that in people with obesity and type 2 diabetes, the endocannabinoid system tends to be overactivated, especially through CB1 receptors. This contributes to greater insulin resistance, more visceral fat accumulation, and poorer metabolic control. This overactivation is not the sole cause of the disease, but it is one more component of the clinical picture.

This is precisely the starting point that has led researchers to wonder if modulating that system with external cannabinoids could have any therapeutic effect on diabetes.

Cannabis and diabetes: what the research says

Before getting into the specific data, it is worth remembering a precedent that no one disputes anymore: cannabinoids can have legitimate and proven medical uses. The clearest example is Epidiolex, a cannabidiol (CBD)-based medication approved by both the FDA and the EMA for the treatment of certain severe types of epilepsy resistant to other drugs, such as Dravet syndrome and Lennox-Gastaut syndrome. Its approval was the result of rigorous clinical trials that demonstrated efficacy and safety.

There is also nabilone, a synthetic cannabinoid approved for the treatment of nausea and vomiting in chemotherapy patients.

This does not mean that cannabis is a cure-all, but it does establish that research on cannabinoids for therapeutic purposes is scientifically serious and has already yielded concrete results in other areas.

In the case of cannabis and diabetes, research is still in the early stages, but there are lines of work that deserve attention:

Cannabinoids and insulin resistance. One of the most cited studies in this field, published in The American Journal of Medicine, analyzed data from more than 4,600 adults and found that current cannabis users had lower fasting insulin levels and lower insulin resistance compared to those who had never used it. They also showed a smaller waist circumference. It is an observational study on cannabis and diabetes, which means it shows an association but does not prove direct causality. Even so, the data are consistent enough to justify deeper research.

CBD and inflammation. Diabetes, especially type 2, has a significant inflammatory component. Preclinical studies have shown that CBD can act as an anti-inflammatory and antioxidant in pancreatic and vascular tissues.

In this context, some users also look for information about formats such as CBD oils, although it is important to remember that these products should not be interpreted as a treatment for diabetes nor replace prescribed medication. There are also varieties and genetics oriented toward profiles rich in cannabidiol, such as CBD seeds, although their use must always be distinguished from any possible medical application for diabetes.

[ppgbo products=”7874,8086,7885″ language=”en”]

Research in animal models with diabetes has observed a reduction in oxidative damage, protection of pancreatic beta cells, and improvement in kidney function. These are results in animals, and translation to humans requires controlled clinical trials that are not yet available, but they point to plausible mechanisms.

THCV and metabolism. Tetrahidrocannabivarin (THCV) is a minor cannabinoid that has aroused interest due to its effects that are apparently opposite to THC in some metabolic aspects and its relationship with THCV and diabetes. Instead of increasing appetite, it seems to reduce it, and some preliminary studies suggest that it could improve glucose tolerance and insulin sensitivity. A small clinical trial published in Diabetes Care explored its use in type 2 diabetes and observed promising results in some metabolic markers, although the sample size was small and larger studies are needed to draw solid conclusions.

THC and glucose: a more complex relationship. THC, the psychoactive cannabinoid par excellence, has a more ambivalent relationship with diabetes. On one hand, some studies suggest that it may have effects on insulin secretion and glucose.

On the other, its effects on perception, appetite, and decision-making can hinder self-control in people with diabetes. Especially regarding recognizing symptoms of hypoglycemia, adhering to medication schedules, or correctly calculating food intake. This point is not minor and deserves special attention in people who use insulin or drugs such as sulfonylureas, which already increase the risk of blood sugar drops.

The relationship between cannabis and diabetes is an active field of research with real scientific foundations. The endocannabinoid system is directly involved in the regulation of glucose metabolism, insulin secretion, and chronic inflammation, all of which are central elements in the pathophysiology of diabetes. This provides a plausible biological basis for further research.

The available studies, both observational in humans and preclinical in animals, suggest that certain cannabinoids such as CBD or THCV could have interesting effects on metabolic markers related to diabetes. The precedent of cannabinoid-based medications already approved for other diseases demonstrates that this type of research can lead to concrete and clinically valid results.

That said, as of today, there is no treatment based on cannabis or cannabinoids specifically approved for diabetes. The available data are promising in some cases, but insufficient to make therapeutic recommendations. Diabetes is a disease that requires continuous medical control, and no person with diabetes should modify their treatment, reduce their insulin, or replace their medication with cannabis or derivatives without medical supervision.

What does make sense is to follow this line of research closely. If ongoing clinical trials confirm the effects observed in preliminary studies, the endocannabinoid system could become a relevant therapeutic target for the treatment of diabetes in the coming years.